



# SIGACHI INDUSTRIES LIMITED

CIN : L24110TG1989PLC009497

To,

Date: January 21, 2026

The Manager  
BSE Limited  
P. J. Towers, Dalal Street  
Mumbai-400001  
(BSE Scrip Code: 543389)

The Manager,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai- 400051.  
(NSE Symbol: SIGACHI)

Dear Sir/Madam,

**Sub: Press Release- Sigachi Industries Achieves Key R&D Milestone in Cystic Fibrosis APIs.**

Sigachi Industries Limited ("Company"), a leading Indian pharmaceutical company, today announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor.

A press release to this extent is enclosed for your information and records.

Thanking you.

Yours Faithfully,  
**For Sigachi Industries Limited**

**Vivek Kumar**  
**Company Secretary & Compliance Officer**



**Registered Office**

#229/1 & 90, 2nd Floor, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad-49, Telangana State, India.  
Customer Service +91 40 40114874-76, E-mail: [info@sigachi.com](mailto:info@sigachi.com), URL: [www.sigachi.com](http://www.sigachi.com)

**Corporate Office**

Plot No. G57/2, Industrial Park, Sultanpur, Hyderabad, Sangareddy (Dist), Telangana - 502319.  
Tel No.: +91-8455-242055 / 56 / 57, E-mail: [enquiry@sigachi.com](mailto:enquiry@sigachi.com), URL: [www.sigachi.com](http://www.sigachi.com)



# SIGACHI INDUSTRIES LIMITED

CIN : L24110TG1989PLC009497

## Sigachi Industries Achieves Key R&D Milestone in Cystic Fibrosis APIs

The Company Advances High-Value Specialty API Portfolio with Annual Revenue Potential of ~₹250 Crore Commencing from Q4 FY 2026–27

**Hyderabad, January 21, 2026:** Sigachi Industries Ltd. (NSE: SIGACHI; BSE: 543389), a leading Indian pharmaceutical company, today announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor.

The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments.

The global cystic fibrosis therapeutics market is estimated to exceed USD 10 billion, driven by growing adoption of next-generation modulator therapies, long-term treatment requirements, and strong pricing resilience. Against this backdrop, Sigachi's entry into CF APIs positions the Company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility.

Based on internal market assessment and strategic evaluation, the Company is actively exploring strategic collaborations with formulation innovators for R&D and future commercial supply of these CF APIs. Subject to successful partnerships and market progression, the Company estimates a revenue potential of approximately ₹250 crore per annum commencing from Q4 FY2026–27, making this portfolio a meaningful growth driver.

Commenting on the development, **Lijo Chacko, Deputy Group CEO, Sigachi Industries Limited**, said, *"This milestone reflects Sigachi's focused strategy of building depth in complex and differentiated APIs with long-term growth visibility. Our continued investments in R&D and partnerships are aimed at strengthening our position in high-entry-barrier specialty segments and creating sustainable value for stakeholders."*

The CF API combination involves advanced chemistry, multi-step synthesis, and specialised reactions, resulting in high technological complexity and significant barriers to entry, thereby limiting competitive intensity and reinforcing Sigachi's capabilities in complex API manufacturing.

Further strengthening long-term visibility, the innovator patent protection for Vanzacaftor extends until 2039, providing sustained collaboration-led commercial opportunity and revenue stability within the cystic fibrosis therapeutic space.

Sigachi Industries continues to focus on strengthening its core businesses while selectively scaling innovation-driven, high-value opportunities aligned with its long-term growth strategy.

### Registered Office

#229/1 & 90, 2nd Floor, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad-49, Telangana State, India.  
Customer Service +91 40 40114874-76, E-mail: [info@sigachi.com](mailto:info@sigachi.com), URL: [www.sigachi.com](http://www.sigachi.com)

### Corporate Office

Plot No. G57/2, Industrial Park, Sultanpur, Hyderabad, Sangareddy (Dist), Telangana - 502319.  
Tel No.: +91-8455-242055 / 56 / 57, E-mail: [enquiry@sigachi.com](mailto:enquiry@sigachi.com), URL: [www.sigachi.com](http://www.sigachi.com)





# SIGACHI INDUSTRIES LIMITED

CIN : L24110TG1989PLC009497

## About Sigachi Industries Ltd

Sigachi Industries Limited is a global player in the pharmaceutical industry dedicated to pioneering advancements in Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral blends, and Operations and Management (O&M) services. The company's diverse product portfolio is manufactured in 5 multilocal facilities, viz. Telangana, Gujarat, and Karnataka. Aligned with its ethos of customer centricity, Sigachi established subsidiaries in UAE and USA to be closer to its clients and improve responsiveness. With a strong focus on innovation, quality, and regulatory compliance, we leverage cutting-edge technology and global expertise to develop high-value pharma, food and nutrition solutions that enhance healthcare outcomes. Committed to excellence, we continuously invest in Research and Development, ensuring the highest standards of quality and safety. With 36 years of industry experience, Sigachi is a trusted partner for pharmaceutical and nutraceutical companies spread across 65+ countries. At Sigachi, we collaborate with healthcare partners, regulatory bodies, and global stakeholders to expand access to reliable, high-quality pharmaceutical ingredients.

## Forward-Looking Statements

*This press release contains forward-looking statements that reflect the current expectations and projections of Sigachi Industries Limited regarding future business performance, research and development initiatives, and strategic growth plans.*

*Forward-looking statements are generally identified by terms such as "aims," "expects," "intends," "plans," "believes," "seeks," "estimates," "potential," "future," and similar expressions. However, actual results may differ materially from those projected due to various risks and uncertainties, including but not limited to regulatory approvals, market dynamics, research outcomes, operational challenges, and broader economic or geopolitical factors.*

*Sigachi Industries Limited undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable laws.*

## For more information, please contact:

The PRactice

Farooque Shaikh - M: +91-9594777764, E: [farooque@the-practice.net](mailto:farooque@the-practice.net)

Sudarshan Dundigal - M: +91-9246371566, E: [vartikapr@gmail.com](mailto:vartikapr@gmail.com)



## Registered Office

#229/1 & 90, 2nd Floor, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad-49, Telangana State, India.  
Customer Service +91 40 40114874-76, E-mail: [info@sigachi.com](mailto:info@sigachi.com), URL: [www.sigachi.com](http://www.sigachi.com)

## Corporate Office

Plot No. G57/2, Industrial Park, Sultanpur, Hyderabad, Sangareddy (Dist), Telangana - 502319.  
Tel No.: +91-8455-242055 / 56 / 57, E-mail: [enquiry@sigachi.com](mailto:enquiry@sigachi.com), URL: [www.sigachi.com](http://www.sigachi.com)